Rhino Biotech Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RBRXF research report →
About the company
Rhino Biotech Limited is dedicated to pioneering the development of health supplements sourced from plants and fungi, in addition to biopharmaceutical solutions designed for both disease prevention and treatment. The company adopted its current name, Rhino Biotech Limited, in September 2021, having previously operated as Eurasia Energy Limited. Established in 2003, its operations are based in South Hill, Anguilla.
- CEO
- Nicholas W. Baxter
- IPO
- 2005
- Employees
- 1
- HQ
- South Hill, AI
Price Chart
- Market Cap
- $3.10K
- P/E
- -0.17
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -2.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 42.73%
- ROIC
- 695.71%
- Revenue
- $0 · 0.00%
- Net Income
- $-21,233 · -3.97%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-21,233
- FCF YoY
- 22.60%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.19
- Avg Volume
- 1.27K
Get TickerSpark's AI analysis on RBRXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RBRXF coverage
Recent articles, reports, and earnings notes.
No research on RBRXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RBRXF report →Similar companies
Peers in the same neighborhood.